Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5K651
UPID:
SAMD9_HUMAN
Alternative names:
-
Alternative UPACC:
Q5K651; A2RU68; Q5K649; Q6P080; Q75N21; Q8IVG6; Q9NXS8
Background:
Sterile alpha motif domain-containing protein 9 (SAMD9) is pivotal in antiviral defense, inflammation response, and possibly in preventing abnormal calcification, as suggested by its role in cytoplasmic antiviral granules formation and TNF-alpha signaling pathway. Its interaction with EGR1 and RGL2 indicates a broader regulatory function in cellular processes.
Therapeutic significance:
SAMD9 mutations are linked to severe disorders such as familial tumoral calcinosis, MIRAGE syndrome, and monosomy 7 myelodysplasia and leukemia syndrome 2. These associations underline the protein's critical role in disease mechanisms, offering a promising avenue for therapeutic interventions targeting SAMD9-related pathways.